1,300 results on '"Jagasia, Madan"'
Search Results
102. Time to Explore Preventive and Novel Therapies for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation
103. Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium
104. Expression of CD30 in patients with acute graft-versus-host disease
105. Genetic Variation in Donor CTLA-4 Regulatory Region is a Strong Predictor of Outcome after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
106. Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies
107. Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen
108. Validation of Measurement Scales in Ocular Graft-versus-Host Disease
109. Risk factors for acute GVHD and survival after hematopoietic cell transplantation
110. Endocrine Complications in Long-Term Survivors After Allogeneic Stem Cell Transplant
111. Efficacy and Safety of Lifileucel, a One-Time Autologous Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy, in Patients With Advanced Melanoma After Progression on Immune Checkpoint Inhibitors and Targeted Therapies: Pooled Analysis of Consecutive Cohorts of the C-144-01 Study
112. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria
113. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts
114. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis
115. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium
116. Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host Disease
117. Pretransplantation C-Peptide Level Predicts Early Posttransplantation Diabetes Mellitus and Has an Impact on Survival after Allogeneic Stem Cell Transplantation
118. Abstract 2746: Preclinical activity and manufacturing feasibility of genetically modified PDCD-1 knockout (KO) tumor-infiltrating lymphocyte (TIL) cell therapy
119. Abstract CT130: Trial in progress: A phase 2 multicenter study (IOV-LUN-202) of autologous tumor-infiltrating lymphocyte (TIL) cell therapy (LN-145) in patients with metastatic non-small cell lung cancer (mNSCLC)
120. Tumor mutational burden (TMB) in immune checkpoint inhibitor (ICI)-naïve and -experienced patients with metastatic melanoma treated with lifileucel, a tumor-infiltrating lymphocyte (TIL) cell therapy.
121. Association of Leukocyte Adhesion and Rolling in Skin With Patient Outcomes After Hematopoietic Cell Transplantation Using Noninvasive Reflectance Confocal Videomicroscopy
122. Validation of International Chronic Ocular Graft-Versus-Host Disease (GVHD) Group Diagnostic Criteria as a Chronic Ocular GVHD-Specific Metric
123. Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study.
124. Diabetes Mellitus after Hematopoietic Stem Cell Transplantation
125. Successful Manufacturing of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy from Cryopreserved Melanoma Tumors Shipped from Australia
126. Bedside Reflectance Confocal Videomicroscopy of Immune Cell Motion in Skin Provides Blood Cancer Insights
127. Sexual health in hematopoietic stem cell transplant recipients
128. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease
129. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation
130. Classic and Overlap Chronic Graft-versus-Host Disease (cGVHD) Is Associated with Superior Outcome after Extracorporeal Photopheresis (ECP)
131. Abstract P050: Trial in progress: A phase 2 multicenter study of autologous tumor-infiltrating lymphocyte (TIL, LN-145) cell therapy in patients with metastatic non-small cell lung cancer (mNSCLC)
132. Machine Learning Reveals Patient Phenotypes and Stratifies Outcomes in Chronic Graft-Versus-Host Disease
133. Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of Iov-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
134. 492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers
135. 458 First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC)
136. Variation in Supportive Care Practices in Hematopoietic Cell Transplantation
137. Assessment of Joint and Fascia Manifestations in Chronic Graft-Versus-Host Disease
138. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
139. Abstract CT246: A phase 2 multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN-145) cell therapy in patients with metastatic non-small cell lung cancer (mNSCLC)
140. Abstract CT008: Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced (unresectable or metastatic) melanoma: durable duration of response at 28 month follow up
141. Abstract CT244: A Phase 1/2 study evaluating the safety and efficacy of IOV-2001 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
142. Abstract CT235: A Phase 2, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN 144/LN-145/LN-145-S1) in patients with solid tumors
143. Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies
144. Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes:EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies
145. Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation
146. Are CAR-T therapies living up to their hype?: A study using real-world data in two cohorts to determine how well they are actually working in practice compared with bone marrow transplants
147. Incidence and Outcome of Chronic Graft-versus-Host Disease Using National Institutes of Health Consensus Criteria
148. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease
149. Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve patients with advanced melanoma.
150. Section 5: Extracorporeal Photopheresis in Chronic Graft-versus-Host Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.